Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19205427 | 0.76 | PDGFRB (0.64) | PDGFRBALDH1A1HTT | |
| SCHEMBL10040322 | 0.75 | PDE10A (0.71) | PDE10AMDM2ALDH1A1LMNAHTT | |
| SCHEMBL10040325 | 0.72 | PDE10A (0.50) | PDE10AMDM2ALDH1A1LMNAHTT | |
| SCHEMBL3810361 | 0.71 | PDE10A (0.47) | PDE10AMDM2ALDH1A1LMNAHTT | |
| SCHEMBL1155787 | 0.71 | MDM2 (0.55) | PDE10AMDM2ALDH1A1LMNAHTT | |
| SCHEMBL7071760 | 0.71 | PDE10A (0.46) | PDE10AMDM2ALDH1A1LMNAHTT | |
| SCHEMBL27344726 | 0.70 | PDE10A (0.48) | PDE10AMDM2ALDH1A1LMNAHTT | |
| SCHEMBL27311732 | 0.70 | ADORA2B (0.44) | PDE10AMDM2ALDH1A1LMNAHTT | |
| SCHEMBL27319191 | 0.69 | NR3C2 (0.44) | PDE10AMDM2ALDH1A1LMNAHTT | |
| SCHEMBL10040326 | 0.68 | GSK3B (0.57) | PDE10AMDM2ALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2604597-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF INHIBITOR OF PHOSPHODIESTERASE 10A | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-04 | — | — | EP | disclosed |
| EP-2604597-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF INHIBITOR OF PHOSPHODIESTERASE 10A | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9150588-B2 | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150588-B2 | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150588-B2 | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| EP-2604597-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-2604597-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137675-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130137675-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130137675-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-30 | — | — | US | disclosed |
| WO-2012020780-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | 武田薬品工業株式会社 (JP) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137675-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | PDE3A, PDE2A, PDE5A | PDE10A 12/4885PDGFRB 3680/4885MDM2 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.